Lumos Diagnostics Holdings (ASX:LDX) Scaled Net Operating Assets: 0.41 (As of Dec. 2025)


ASX:LDX Lumos Diagnostics Holdings Ltd ASX:LDX
31 GF Score
Price A$0.11
GF Value A$0.02
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Lumos Diagnostics Holdings Scaled Net Operating Assets?

Lumos Diagnostics Holdings ASX:LDX 31 Scaled Net Operating Assets is 0.41 as of Dec. 2025. GuruFocus rates ASX:LDX with a GF Score™ of 31/100 and a GF Value™ of A$0.02 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Lumos Diagnostics Holdings's operating assets for the quarter that ended in Dec. 2025 was A$27.25 Mil. Lumos Diagnostics Holdings's operating liabilities for the quarter that ended in Dec. 2025 was A$14.15 Mil. Lumos Diagnostics Holdings's Total Assets for the quarter that ended in Jun. 2025 was A$31.97 Mil. Therefore, Lumos Diagnostics Holdings's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2025 was 0.41.

Lumos Diagnostics Holdings Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Lumos Diagnostics Holdings's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lumos Diagnostics Holdings Scaled Net Operating Assets Chart

Lumos Diagnostics Holdings Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Scaled Net Operating Assets
0.46 0.46 0.35 0.43

Lumos Diagnostics Holdings Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.65 0.38 0.47 0.41 0.41

ASX:LDX vs ABT, SYK, MDT: Scaled Net Operating Assets Comparison

For the Medical Devices subindustry, Lumos Diagnostics Holdings's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lumos Diagnostics Holdings Scaled Net Operating Assets vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Lumos Diagnostics Holdings's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Lumos Diagnostics Holdings's Scaled Net Operating Assets falls into.


ASX:LDX
31GF Score
Lumos Diagnostics Holdings Ltd ASX:LDX
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lumos Diagnostics Holdings Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Lumos Diagnostics Holdings's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Jun. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(A: Jun. 2025 )
=(Operating Assets (A: Jun. 2025 )-Operating Liabilities (A: Jun. 2025 ))/Total Assets (A: Jun. 2024 )
=(28.963-11.781)/40.418
=0.43

where

Operating Assets(A: Jun. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=31.967 - 3.004
=28.963

Operating Liabilities(A: Jun. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=22.51 - 9.124 - 1.605
=11.781

Lumos Diagnostics Holdings's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Dec. 2025 )
=(Operating Assets (Q: Dec. 2025 )-Operating Liabilities (Q: Dec. 2025 ))/Total Assets (Q: Jun. 2025 )
=(27.254-14.149)/31.967
=0.41

where

Operating Assets(Q: Dec. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=31.76 - 4.506
=27.254

Operating Liabilities(Q: Dec. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=23.886 - 8.088 - 1.649
=14.149

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of 0.41 mean?
Lumos Diagnostics Holdings (ASX:LDX) has a Scaled Net Operating Assets of 0.41 as of Dec. 2025. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Lumos Diagnostics Holdings and its competitors.
Is Lumos Diagnostics Holdings' Scaled Net Operating Assets too high?
Lumos Diagnostics Holdings' current Scaled Net Operating Assets is 0.41. Overall, Lumos Diagnostics Holdings has a GF Score™ of 31/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lumos Diagnostics Holdings' Scaled Net Operating Assets compare to ABT and SYK?
Lumos Diagnostics Holdings' Scaled Net Operating Assets of 0.41 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Medical Devices & Instruments company?
A good Scaled Net Operating Assets depends on the Medical Devices & Instruments industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Lumos Diagnostics Holdings and its competitors. Lumos Diagnostics Holdings's current Scaled Net Operating Assets is 0.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumos Diagnostics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Lumos Diagnostics Holdings (ASX:LDX) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.02, compared to a current price of A$0.11 — trading 425% above its estimated fair value. The current Scaled Net Operating Assets is 0.41. Lumos Diagnostics Holdings' overall GF Score™ is 31/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Lumos Diagnostics Holdings (ASX:LDX), the current Scaled Net Operating Assets is 0.41 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lumos Diagnostics Holdings (ASX:LDX) Overvalued in 2026?

Based on GuruFocus' analysis, Lumos Diagnostics Holdings stock appears to be overvalued. The current stock price of A$0.11 is trading 425% above its estimated GF Value™ of A$0.02. GuruFocus considers Lumos Diagnostics Holdings to be Significantly Overvalued.

Key valuation signals for ASX:LDX:

  • Scaled Net Operating Assets: 0.41
  • GF Value™: A$0.02 vs. price of A$0.11 (425% above fair value)
  • GF Score™: 31/100 with 7 warning signs

No single metric tells the full story. See the ASX:LDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lumos Diagnostics Holdings Business Description

Other Exchanges LDXHF:USA
Address 2724 Loker Avenue West, Carlsbad, CA, USA, 92010
Lumos Diagnostics Holdings Ltd is engaged in the development, manufacture, and distribution of point-of-care diagnostic (POC) tests and associated readers for analysis of POC diagnostic tests. The group is dedicated to providing contract research and development services, focusing on the innovation, development, manufacturing, and commercialization of point-of-care diagnostic solutions for both clinical and consumer applications. It generates maximum revenue from commercial services and solutions relating to POC diagnostic tests. The group has one operating segment, which is the provision of point-of-care diagnostics goods and services. The Company operates in two geographical regions, the United States and Australia and the majority of revenue is generated from the United States.
31GF Score

Get the complete analysis for ASX:LDX

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.11
Price
A$0.02
GF Value